Trial Profile

Acute Effect of Lemborexant on CSF Amyloid-Beta and Tau

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 14 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lemborexant (Primary)
Indications Chronic obstructive pulmonary disease; Circadian rhythm sleep disorders; Insomnia; Sleep apnoea syndrome
Focus Pharmacodynamics

Most Recent Events

03 Nov 2023 Status changed from recruiting to withdrawn prior to enrolment.
01 Mar 2023 Planned End Date changed from 1 Jan 2025 to 1 Mar 2025.
01 Mar 2023 Planned primary completion date changed from 1 Jan 2025 to 1 Mar 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com